Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $221.2652W HIGH $362.41
Volume
165.43 K
Value Traded
63.47 M
Short % Float
5.87%
Days to Cover
4.8
+0.86%Week
+1.88%1 Month
+1.78%3 Month
-0.85%6 Month
+29.16%5 Year
+721.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
12.80 B
EPS (TTM)
4.08
P/E Ratio
79.76
Ent. Value
12.15 B
Total Shares
39.39 M
Float Shares
38.26 M
Insiders
2.87%
Institutions
87.22%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PEN Catalyst Timeline
Dated clinical, regulatory and corporate events for Penumbra, Inc.
Past FDA Catalysts and PDUFA Decisions
How PEN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 89%
Mid Cap(rank 585 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every PEN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| computer-assisted vacuum thrombectomy (CAVT) | pulmonary embolism | 2026-10-06 | Total daily step count, walking bout length, number of walking bouts, walking bout duration and peak 10-minute step count were significantly correlated with 30-day 6-minute walk test performance.; Correlations were strongest with temporally matched wearable and clinic data at 30 days and attenuated with 90-day follow up data.Read More | New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary EmbolismRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Elsesser AdamDirector, Officer (CEO) | Disposition | -77,000 683,042 held | $0.00 | 05/19/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PEN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PFM HEALTH SCIENCES, LP | 1.6 % (-61.9 %) | 19.01 M | 60.22 K | -56.92% ( -79.56 K) |
PEN Institutional Ownership Trends
PEN Short Interest
Shares sold short, counted twice a month.
5.87%
Short % of Float
of tradable shares sold short
2.2M
Shares Sold Short
+24.3% vs prior count
4.8 Moderate
Days to Cover
trading days of normal volume to buy every short share back
472.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PEN ranks across every disease it competes in
Competitive Position is a premium feature
See how PEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPEN News
PENPenumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)
Penumbra, Inc. has received FDA clearance for its Lightning™ computer assisted vacuum thrombectomy (CAVT™) technology for treating deep vein thrombosis (DVT). This approval follows positive results from the BOLT-DVT trial, which showed the technology's safety and efficacy, including rapid clot removal and significant patient-reported improvements in pain and quality of life. The trial highlighted the potential of CAVT to enhance DVT treatment protocols.
Read more →PENNew STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism
Penumbra, Inc. announced positive results from the STORM-PE trial, showing a correlation between real-world activity tracked by wearables and clinical assessments in pulmonary embolism patients. The trial demonstrated that patients receiving computer-assisted vacuum thrombectomy (CAVT) plus anticoagulation had better recovery outcomes compared to those on anticoagulation alone. These findings were presented at the VIVA meeting, highlighting the potential of wearables in enhancing patient care.
Read more →PENIncuvate Files Patent Infringement Lawsuit Against Penumbra
Incuvate, LLC has initiated a patent infringement lawsuit against Penumbra, Inc. in the U.S. District Court for the Northern District of California. The lawsuit claims that Penumbra's THUNDERBOLT Neurovascular Thrombectomy System infringes on five of Incuvate's patents related to real-time aspiration monitoring technology. Incuvate seeks damages and injunctive relief, alleging unauthorized use of their patented technology.
Read more →PENPenumbra, Inc. Reports Second Quarter 2026 Financial Results
Penumbra, Inc. reported strong financial results for Q2 2026, with revenues reaching $390 million, a 14.9% increase from the previous year. The company saw notable growth in both thrombectomy and embolization segments. However, due to a pending acquisition by Boston Scientific, Penumbra will not provide financial guidance for the remainder of the year.
Read more →PENTHUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care
The THUNDER study has shown that Penumbra's THUNDERBOLT device is both safe and effective for treating stroke patients with emergent large vessel occlusion. The device demonstrated a high rate of complete clot ingestion and low complication rates. With a median time-to-revascularization of just 20 minutes, the study results support the advancement of mechanical thrombectomy technologies. THUNDERBOLT has also received FDA clearance and CE Mark.
Read more →PENFirst Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
Penumbra, Inc. has initiated its FORWARD study, focusing on mechanical thrombectomy for distal acute ischemic strokes. The study aims to evaluate the safety and efficacy of its RED reperfusion catheter portfolio, which includes the THUNDERBOLT CAVT platform. The first patient has been treated, marking a key milestone in addressing a challenging patient population with limited treatment options.
Read more →PENPenumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT
Penumbra, Inc. has received CE Mark approval for its THUNDERBOLT technology, which enables advanced computer-assisted vacuum thrombectomy for acute ischemic stroke. This marks a significant step in expanding access to innovative stroke care in Europe, following recent FDA clearance in the U.S. The technology aims to enhance patient outcomes and streamline treatment procedures.
Read more →PENPenumbra's THUNDERBOLT Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology to Stroke
Penumbra, Inc. has received FDA clearance for its THUNDERBOLT technology, the first computer-assisted vacuum thrombectomy platform aimed at treating acute ischemic stroke. This innovative system enhances clot removal efficiency and safety, potentially improving patient recovery outcomes. THUNDERBOLT is set to redefine stroke management by minimizing catheter manipulation and ensuring complete clot capture.
Read more →PENPenumbra, Inc. Reports First Quarter 2026 Financial Results
Penumbra, Inc. reported strong financial results for Q1 2026, with revenues reaching $374.8 million, a 15.6% increase from the previous year. The company saw significant growth in both thrombectomy and embolization revenues. However, it has opted not to provide financial guidance for the full year due to its pending acquisition by Boston Scientific Corporation.
Read more →PENNew STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients
Penumbra, Inc. announced positive 90-day results from the STORM-PE trial, showing that patients with acute intermediate-high risk pulmonary embolism treated with computer assisted vacuum thrombectomy (CAVT) plus anticoagulation had significantly better functional outcomes compared to those receiving anticoagulation alone. The trial demonstrated improvements in walking distance and functional status, highlighting the potential of CAVT in enhancing patient recovery.
Read more →PENPenumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
Penumbra, Inc. reported strong financial results for Q4 and full year 2025, with total revenue reaching $385.4 million for Q4, a 22.1% increase from the previous year. The company also saw a rise in gross profit margin and income from operations. However, it will not provide guidance for 2026 due to a pending acquisition by Boston Scientific.
Read more →PEN▲ +11.8%on this newsshared move
Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results
Penumbra reported preliminary fourth quarter revenue between $383.0 million and $384.8 million. This marks growth of approximately 21.4% to 22.0% compared to the prior year period. Full year revenue reached $1,401.3 million to $1,403.1 million. That represents an increase of roughly 17.3% to 17.5% over 2024 results.
Read more →PENPenumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference
Penumbra, Inc. is set to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be available via a webcast on the company's website for at least two weeks post-event. Penumbra is known for its innovative thrombectomy technologies aimed at improving patient outcomes in various medical conditions.
Read more →PENPenumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference
Penumbra, Inc. announced that its management team will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. The presentation will be accessible via a webcast on the company's website, which will remain available for two weeks post-event. Penumbra focuses on innovative thrombectomy technologies aimed at improving patient outcomes.
Read more →PEN▲ +17.3%on this news
Penumbra, Inc. Reports Third Quarter 2025 Financial Results
Penumbra, Inc. reported strong financial results for Q3 2025, with total revenue reaching $354.7 million, a 17.8% increase from the previous year. The company also raised its full-year revenue guidance to between $1.375 billion and $1.380 billion, reflecting confidence in continued growth. Gross profit margin improved to 67.8%, although operating expenses rose compared to the prior year.
Read more →PENLatest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism
Penumbra, Inc. announced positive results from the STORM-PE trial, showing that computer-assisted vacuum thrombectomy (CAVT) combined with anticoagulation significantly improves functional outcomes for patients with acute pulmonary embolism. The trial demonstrated superior thrombus reduction and recovery rates compared to anticoagulation alone. These findings highlight the importance of early intervention and may influence future treatment guidelines.
Read more →PENLandmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism
Penumbra, Inc. announced positive results from the STORM-PE trial, demonstrating that computer assisted vacuum thrombectomy (CAVT) combined with anticoagulation significantly reduces right heart strain in patients with acute pulmonary embolism compared to anticoagulation alone. The study involved 100 patients across 22 sites and showed a higher rate of normalization of RV/LV ratio without increased complications. These findings could influence future treatment guidelines for pulmonary embolism.
Read more →PENPenumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025
Penumbra, Inc. will host an investor event on October 26, 2025, at the TCT Conference, focusing on the STORM-PE clinical trial. A conference call for third quarter financial results is scheduled for November 5, 2025. The events will be accessible via webcast, emphasizing the company's commitment to transparency and investor engagement.
Read more →PENPenumbra, Inc. Names Shruthi Narayan as Company President
Penumbra, Inc. has announced the promotion of Shruthi Narayan to President, effective September 1, 2025. Narayan, a seasoned leader with 20 years in the medical device industry, previously led the company's interventional business. Her appointment is expected to drive continued growth and innovation in Penumbra's life-saving technologies.
Read more →PENPenumbra, Inc. to Present at Upcoming Investor Conferences
Penumbra, Inc. has announced its participation in two upcoming investor conferences: the Wells Fargo Healthcare Conference on September 3, 2025, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The presentations will be accessible via webcasts on the company's website for at least two weeks after each event. Penumbra is known for its advancements in thrombectomy technologies.
Read more →About Penumbra, Inc.
HeadquartersONE PENUMBRA PLACE, ALAMEDA, CA, 94502
BIOPHARMAWATCH ELITE PLUS
Trade the next PEN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime